Concepts (125)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ophthalmology | 3 | 2018 | 27 | 1.090 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2016 | 83 | 0.850 |
Why?
|
| Triamcinolone Acetonide | 3 | 2009 | 14 | 0.560 |
Why?
|
| Musculoskeletal Diseases | 2 | 2012 | 105 | 0.530 |
Why?
|
| Endophthalmitis | 2 | 2015 | 16 | 0.510 |
Why?
|
| Glucocorticoids | 3 | 2009 | 190 | 0.500 |
Why?
|
| Occupational Diseases | 2 | 2012 | 266 | 0.490 |
Why?
|
| Patient Satisfaction | 2 | 2021 | 441 | 0.460 |
Why?
|
| Anterior Eye Segment | 1 | 2015 | 6 | 0.450 |
Why?
|
| Retinal Vein Occlusion | 4 | 2015 | 18 | 0.420 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 425 | 0.420 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2016 | 234 | 0.420 |
Why?
|
| Diabetic Retinopathy | 1 | 2015 | 60 | 0.410 |
Why?
|
| Macular Degeneration | 3 | 2011 | 196 | 0.380 |
Why?
|
| Optometry | 1 | 2012 | 8 | 0.360 |
Why?
|
| Macular Edema | 3 | 2015 | 24 | 0.340 |
Why?
|
| Physicians, Family | 1 | 2012 | 76 | 0.340 |
Why?
|
| Eye Pain | 1 | 2011 | 4 | 0.340 |
Why?
|
| Anesthesia, Local | 1 | 2011 | 20 | 0.330 |
Why?
|
| Choroidal Neovascularization | 2 | 2008 | 28 | 0.330 |
Why?
|
| Anesthetics, Local | 1 | 2011 | 73 | 0.320 |
Why?
|
| Photochemotherapy | 2 | 2008 | 46 | 0.320 |
Why?
|
| Ranibizumab | 3 | 2016 | 22 | 0.310 |
Why?
|
| Visual Field Tests | 1 | 2009 | 24 | 0.300 |
Why?
|
| Hydroxychloroquine | 1 | 2009 | 19 | 0.300 |
Why?
|
| Retinal Diseases | 1 | 2009 | 34 | 0.290 |
Why?
|
| Uveomeningoencephalitic Syndrome | 1 | 2008 | 4 | 0.280 |
Why?
|
| Vascular Neoplasms | 1 | 2008 | 18 | 0.270 |
Why?
|
| Visual Acuity | 6 | 2016 | 137 | 0.270 |
Why?
|
| Choroid | 1 | 2008 | 17 | 0.270 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2008 | 46 | 0.260 |
Why?
|
| Lymphoma | 1 | 2008 | 101 | 0.260 |
Why?
|
| Fluorescein Angiography | 5 | 2008 | 63 | 0.250 |
Why?
|
| Antirheumatic Agents | 1 | 2009 | 227 | 0.250 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2016 | 37 | 0.230 |
Why?
|
| Vitreous Body | 4 | 2011 | 31 | 0.220 |
Why?
|
| Wet Macular Degeneration | 2 | 2016 | 24 | 0.220 |
Why?
|
| Intravitreal Injections | 3 | 2016 | 55 | 0.220 |
Why?
|
| Neck Pain | 1 | 2005 | 21 | 0.220 |
Why?
|
| Back Pain | 1 | 2005 | 49 | 0.210 |
Why?
|
| Angioplasty, Balloon | 1 | 2004 | 55 | 0.210 |
Why?
|
| Eye | 1 | 2004 | 59 | 0.210 |
Why?
|
| Carotid Artery, Internal | 1 | 2004 | 69 | 0.210 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2016 | 501 | 0.200 |
Why?
|
| Carotid Stenosis | 1 | 2004 | 100 | 0.200 |
Why?
|
| Male | 14 | 2018 | 31208 | 0.200 |
Why?
|
| Bevacizumab | 2 | 2015 | 61 | 0.190 |
Why?
|
| Ischemia | 1 | 2004 | 203 | 0.190 |
Why?
|
| Aged, 80 and over | 7 | 2016 | 5650 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2015 | 253 | 0.160 |
Why?
|
| Stents | 1 | 2004 | 500 | 0.160 |
Why?
|
| Female | 11 | 2018 | 34216 | 0.160 |
Why?
|
| Aged | 8 | 2018 | 15062 | 0.150 |
Why?
|
| Humans | 16 | 2021 | 65498 | 0.140 |
Why?
|
| Middle Aged | 8 | 2018 | 18393 | 0.140 |
Why?
|
| Injections | 3 | 2009 | 84 | 0.140 |
Why?
|
| Retina | 3 | 2021 | 135 | 0.140 |
Why?
|
| Consumer Behavior | 1 | 2018 | 38 | 0.140 |
Why?
|
| Porphyrins | 2 | 2008 | 10 | 0.130 |
Why?
|
| Photosensitizing Agents | 2 | 2008 | 32 | 0.130 |
Why?
|
| Trust | 1 | 2018 | 80 | 0.130 |
Why?
|
| Health Care Surveys | 1 | 2018 | 288 | 0.130 |
Why?
|
| Prospective Studies | 3 | 2015 | 3326 | 0.120 |
Why?
|
| Subretinal Fluid | 1 | 2016 | 3 | 0.120 |
Why?
|
| Telemedicine | 1 | 2021 | 373 | 0.120 |
Why?
|
| Double-Blind Method | 3 | 2016 | 744 | 0.110 |
Why?
|
| Photometry | 1 | 2015 | 7 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 2 | 2011 | 875 | 0.110 |
Why?
|
| Quality of Health Care | 1 | 2018 | 533 | 0.100 |
Why?
|
| Homocysteine | 2 | 2005 | 33 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 708 | 0.090 |
Why?
|
| Tetracaine | 1 | 2011 | 7 | 0.080 |
Why?
|
| Propoxycaine | 1 | 2011 | 5 | 0.080 |
Why?
|
| Lidocaine | 1 | 2011 | 33 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2009 | 6939 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 2725 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 2778 | 0.080 |
Why?
|
| Drug Therapy, Combination | 2 | 2008 | 463 | 0.080 |
Why?
|
| Pain Measurement | 1 | 2011 | 343 | 0.080 |
Why?
|
| Arthritis | 1 | 2009 | 52 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2009 | 5811 | 0.070 |
Why?
|
| Fovea Centralis | 1 | 2009 | 15 | 0.070 |
Why?
|
| Prednisolone | 1 | 2008 | 11 | 0.070 |
Why?
|
| Vincristine | 1 | 2008 | 26 | 0.070 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2008 | 33 | 0.070 |
Why?
|
| Cyclophosphamide | 1 | 2008 | 84 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 58 | 0.070 |
Why?
|
| Doxorubicin | 1 | 2008 | 98 | 0.070 |
Why?
|
| Blood Vessels | 1 | 2008 | 63 | 0.070 |
Why?
|
| Rituximab | 1 | 2008 | 89 | 0.070 |
Why?
|
| Vision Disorders | 1 | 2008 | 69 | 0.070 |
Why?
|
| Diclofenac | 1 | 2007 | 5 | 0.070 |
Why?
|
| Regional Blood Flow | 1 | 2008 | 116 | 0.070 |
Why?
|
| Biopsy | 1 | 2008 | 460 | 0.060 |
Why?
|
| Tomography, Optical Coherence | 2 | 2009 | 236 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2009 | 1021 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2007 | 202 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2008 | 990 | 0.060 |
Why?
|
| Fluorescein | 1 | 2005 | 13 | 0.060 |
Why?
|
| Ophthalmic Artery | 1 | 2004 | 6 | 0.050 |
Why?
|
| Self Disclosure | 1 | 2005 | 37 | 0.050 |
Why?
|
| Blood Chemical Analysis | 1 | 2005 | 20 | 0.050 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2004 | 25 | 0.050 |
Why?
|
| United States | 1 | 2018 | 8149 | 0.050 |
Why?
|
| Skin | 1 | 2008 | 428 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 465 | 0.050 |
Why?
|
| New England | 1 | 2005 | 271 | 0.050 |
Why?
|
| Diagnostic Errors | 1 | 2005 | 106 | 0.050 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2004 | 186 | 0.050 |
Why?
|
| Health Surveys | 1 | 2005 | 317 | 0.050 |
Why?
|
| Hyperhomocysteinemia | 1 | 2002 | 6 | 0.050 |
Why?
|
| Health Personnel | 1 | 2005 | 389 | 0.040 |
Why?
|
| Prevalence | 1 | 2005 | 1451 | 0.040 |
Why?
|
| Risk Factors | 2 | 2008 | 5462 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 2495 | 0.030 |
Why?
|
| Time Factors | 1 | 2005 | 3774 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 687 | 0.030 |
Why?
|
| Adult | 3 | 2009 | 17467 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2016 | 166 | 0.030 |
Why?
|
| Ophthalmic Solutions | 1 | 2007 | 8 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2007 | 51 | 0.020 |
Why?
|
| Fluorescence Polarization Immunoassay | 1 | 2005 | 8 | 0.010 |
Why?
|
| Artifacts | 1 | 2005 | 128 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2002 | 1143 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2002 | 555 | 0.010 |
Why?
|